Loading…
Traded Jun 3, 2026 · Filed Jun 5, 2026
Dexcom's Chief Commercial Officer sold $359K of Dexcom shares. It was planned long ago, so it says very little.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
open market sale
Code S — open-market or private sale
~$358,576
Shares × reported transaction price
34 days after results of Apr 30, 2026, 57 days before results of Jul 30, 2026
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $72.77 on Jun 3, 2026, 33% above its 52-week low and 19% below its high, after a 16% rise over the previous 30 trading days
52-week range $54.84 (Nov 10, 2025) to $89.53 (Jul 28, 2025), 52% of the way up, from 251 adjusted closes. 30 trading days earlier: $62.60 on Apr 21, 2026. Describes the past only, not a forecast
Footnote references a pre-arranged trading plan (Rule 10b5-1)
Only flagged when a footnote says so; never inferred
A securities lawsuit naming the company as a defendant was filed on Oct 27, 2025 in the U.S. District Court, S.D. New York. A filing is an allegation, not a finding.
4 such cases were open. Prime v. DexCom, Inc., docket 1:25-cv-08912, via CourtListener (court records). Nature of suit 850, company named as first defendant
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | -3.1% | +2.1% | -5.2% |
| 30 days | -3.3% | +0.8% | -4.2% |
| 90 days | +10.3% | +3.6% | +6.7% |
Past results only. Not a forecast.